The FDA approved a supplemental application for Empaveli (pegcetacoplan) on 2025-07-28. This approval specifically pertains to the drug's efficacy, expanding its regulatory scope.
Background
Empaveli (pegcetacoplan) is a medication developed by Apellis Pharmaceuticals. This supplemental approval for efficacy represents an update to the drug's existing profile.
What this means
This supplemental efficacy approval signifies that the FDA has reviewed and accepted additional data supporting the effectiveness of Empaveli. For healthcare professionals, researchers, and patient advocates, this action confirms an expanded understanding of pegcetacoplan's therapeutic benefits, potentially leading to broader application or refined treatment guidelines based on the new efficacy data.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA) website. Details for supplemental application NDA 215014 S-11 were posted on 2025-07-28 on accessdata.fda.gov.